Phase 3
Completed N=65
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Oropharynx Cancer
Source: ClinicalTrials.gov NCT03269344 ↗
Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcomePrimary: Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up — 20.1; 29.1 score on a scale — p=0.11
◆ Published Evidence
Established
20citations · ~5 / year
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Summary
Strategies to minimize and mitigate external beam radiation therapy related mucositis and pain during the treatment of head and neck cancer remain limited. The investigators hypothesize that gabapentin could be used to delay or reduce treatment-related pain, reliance on opioid medication, and improve the quality of life for these patients.
Linked Publications
-
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up |
20.1; 29.1 | 0.11 |
| SECONDARY Change in Total FACT-HN Scores From Baseline to Follow-up |
-15.0; -20.0 | 0.08 |
| SECONDARY Average Opioid Use, Measured in Morphine Equivalents Per Day. |
15.6; 22.2 | 0.32 |
| SECONDARY Change in PRO-CTCAE Scores From Baseline to Follow-up |
1.0; 6.5 | <0.01 sig |
| SECONDARY Percent Weight Lost |
-10.7; -11.4 | 0.81 |
| SECONDARY Feeding Tube Placement |
6; 18 | <0.01 sig |
Eligibility Criteria
Inclusion Criteria
- Patients being treated with combination chemotherapy and radiation therapy daily for locally advanced (stage III-IV) squamous cell carcinoma of the oropharynx.
- Age ≥ 18.
- ECOG performance status ≤ 1.
- Patients must provide study specific informed consent prior to study entry and be able to fill out toxicity and quality of life related questionnaires.
Exclusion Criteria
- Patients may not be receiving gabapentin, any other investigational agents, or other anticonvulsants.
- Patients with metastatic disease are excluded from this clinical trial.
- Patient with allergies or hypersensitivity to gabapentin.
- Patients receiving surgery as part of their definitive management.
- Patients who have received prior chemotherapy or radiation therapy.
- Patients unable to complete the required forms; however, verbal completion is adequate if recorded on the form daily.
- Uncontrolled serious illness including, but not limited to, ongoing or serious active infection requiring IV antibiotics for over 30 days, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements.
Data sourced from ClinicalTrials.gov (NCT03269344) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.